Kenneth Song
Fortune : 334 200 $ au 31/05/2026
Fortune : 334 200 $ au 31/05/2026
Kenneth Song was the founder of Ariosa Diagnostics, Inc., founded in 2008, where the title held was Chief Executive Officer from 2010 to 2016.
Dr. Song was the founder of Abbott Pharmaceuticals (Shanghai) Co., Ltd., founded in 2021, where the title held was Chairman from 2021 to 2025.
Dr. Song is currently Chairman, President & Chief Executive Officer at Candid Therapeutics, Inc. since 2024.
Dr. Song is currently Executive Chairman at Averto Medical, Inc. since 2024.
Dr. Song is currently Independent Director at Perceptive Capital Solutions Corp.
since 2024.
Former positions include President, Chief Executive Officer & Director at Metacrine, Inc. from 2016 to 2020.
President, Chief Executive Officer & Director at Rayzebio, Inc. from 2020 to 2024.
Executive Chairman at Omniome LLC from 2017 to 2021.
Vice President at Venrock Associates from 2007 to 2010.
Consultant at McKinsey & Co., Inc. Education includes undergraduate degree from Massachusetts Institute of Technology and doctorate from The University of California, San Francisco.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
1,39 % | 01/05/2026 | 30 000 ( 1,39 % ) | 334 200 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|
| Sociétés | Poste | Fin |
|---|---|---|
Ablaze Pharmaceuticals
Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of radiopharmaceutical therapies to treat cancer patients | Fondateur | 01/01/2025 |
| RAYZEBIO, INC. | Directeur Général | 26/02/2024 |
Omniome LLC
Omniome LLC Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy | Président | 01/09/2021 |
| METACRINE, INC. | Directeur Général | 09/06/2020 |
Ariosa Diagnostics, Inc.
Ariosa Diagnostics, Inc. Medical/Nursing ServicesHealth Services Offers diagnostics and genetic testing services | Directeur Général | 01/04/2016 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 9 |
|---|---|
Venrock Associates
Venrock Associates Investment ManagersFinance Venrock Associates invests in companies located in the US. The firm focuses on sectors such as intelligent enterprise & AI, security & infrastructure, fintech, healthcare IT, defense & Aerospace, robotics & autonomy and consumer sectors. It participates in early and later stage transactions. | Finance |
Omniome LLC
Omniome LLC Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy | Commercial Services |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ariosa Diagnostics, Inc.
Ariosa Diagnostics, Inc. Medical/Nursing ServicesHealth Services Offers diagnostics and genetic testing services | Health Services |
Metacrine, Inc.
Metacrine, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in discovery and development of therapies for patients with liver and gastrointestinal diseases | Health Technology |
Rayzebio, Inc.
Rayzebio, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapeutics for cancer treatment | Health Technology |
Ablaze Pharmaceuticals
Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of radiopharmaceutical therapies to treat cancer patients | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national